[Treatment of refractory spondylarthropathies].
Dubost
J J
JJ
Unité d'Immunologie clinique, CHU Gabriel Montpied, Clermont-Ferrand.
Soubrier
M
M
Sauvezie
B
B
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D006801:Humans; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D008775:Methylprednisolone / Q000008:administration & dosage / Q000009:adverse effects; D012008:Recurrence; D013167:Spondylitis, Ankylosing / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D012460:Sulfasalazine / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D012460:Sulfasalazine; D008775:Methylprednisolone; D008727:Methotrexate
Traitement des spondylarthropathies réfractaires.